Biohit Oyj - Company Announcement

GastroPanel validation for Dynex automate completed

Biohit Oyj Stock Exchange Release April 14, 2014 at 10:00 am local time (EET)


The project to validate GastroPanel for Dynex Technologies´ DS2 - ELISA
automate has been completed.  DS2 operators can now run GastroPanel according
to a protocol that has been validated by Biohit. The installed base of DS2 is
more than 1,000 units worldwide. 

The Dynex automated ELISA systems, will improve the availability and usability
of the GastroPanel. With the help of this integrated system solution, small and
medium-sized laboratories will be able to perform GastroPanel easily and
cost-effectively. 


Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com


Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit's
mission is “Innovating for Health” - we produce innovative products and
services to promote research and early diagnosis. Biohit is headquartered in
Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B
share (BIOBV) is quoted on NASDAQ OMX Helsinki in the Small cap/Healthcare
group. www.biohithealthcare.com 


Dynex Technologies in brief

Dynex (www.dynextechnologies.com) pioneered microplate technology more than 50
years ago, and has since delivered a series of cutting edge, best-of-class
processing systems, including the 4-plate DSX and 2-plate DS2 systems, and the
newly released Agility 12-plate system.  Dynex designs each of its products to
meet the rigorous demands of scientists in clinical, biomedical, and
pharmaceutical development applications.  Dynex is based in Chantilly,
Virginia, USA, with locations in Hong Kong, Germany and the UK, and markets its
products worldwide.

Attachments:

Additional information about GastroPanel.pdf